An illustration of data network overlaid on a dotted patient image to symbolizing biomarker discovery
An illustration of data network overlaid on a dotted patient image to symbolizing biomarker discovery

Therapeutic Intelligence via Genialis Supermodel

The Supermodel has been trained to learn ground truth biology, capturing 100s of therapeutically relevant facets of cancer. This approach contrasts with training a model on specific outcomes from limited cohorts, and contrasts with throwing a pile of data into a computer to find unintelligible patterns. Rather, our methods yield highly interpretable outputs, and allow us to support translational and clinical decision making from beginning to end.

Preclinical

Elucidate mechanism of action & causes of resistance

Identify complex biomarkers to impact clinical decision making

Early-Clinical Development

Stratify patients into explainable subgroups

Predict patient benefit and duration of response

Late-Clinical Development

CTA development and validation with CLIA/CAP Diagnostic provider

Nominate combination and sequential therapies

a patient presented as a collection of dots

Understand your patient and your drug

Genialis Supermodel derives interpretable biological traits from messy transcriptomic data.
These traits are informative on their own, but can also be used in predictive modelling.

Get more with less

Using the Supermodel, integrate and extract value from small datasets prevalent in clinical development.

Benefit from the Supermodel early in the drug’s lifecycle

Generate insights from preclinical sequencing data. Build clinical models before you collect response data.

Integrate the Supermodel into your research workflows

Plug Genialis Supermodel into your software, AI, and data ecosystem. Or complement your research with our team’s expertise.

End to end drug development support

Across early translational stages where only preclinical data are available through late-stage translation and diagnostics.

Preclinical > IND
Phase I, IIa, IIb

Therapeutic intelligence via the Genialis Supermodel

Gain insights on the molecular mechanisms of response/ resistance
Propose rational combination strategies according to the MoA of the drug
Develop a clinically actionable predictive biomarker for patient selection and stratification
Investigate drug’s biological MOA, safety, DMPK, and resistance
Identify biological processes influencing the drug’s safety and efficacy
Inform mono vs. combination therapy

Genialis + Diagnostic partner

Develop a Clinical Trial Assay (CTA) and/or Companion Diagnostic (CDx)

End to end drug development support

Across early translational stages where only preclinical data are available through late-stage translation and diagnostics.

Preclinical > IND
Phase I, IIa, IIb

Therapeutic intelligence via the Genialis Supermodel

Gain insights on the molecular mechanisms of response/ resistance
Propose rational combination strategies according to the MoA of the drug
Develop a clinically actionable predictive biomarker for patient selection and stratification
Investigate drug’s biological MOA, safety, DMPK, and resistance
Identify biological processes influencing the drug’s safety and efficacy
Inform mono vs. combination therapy

Genialis + Diagnostic partner

Develop a Clinical Trial Assay (CTA) and/or Companion Diagnostic (CDx)

Differentiate your drug with compound-specific intelligence

Gain a competitive edge with better-informed decision-making and execution

A foundation model of cancer biology

Trained to understand therapeutically relevant biology

Genialis™ krasID

The first and only biomarker that can accurately stratify KRAS patients by clinical response

DDR biomarker

An algorithm system for DNA Damage Response agents to identify responders to WEE1 inhibition